Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc.

Kahn Swick & Foti is investigating the proposed acquisition of Supernus Pharmaceuticals by Indivior. Supernus shareholders would receive 1.5401 Indivior common shares for each Supernus share held. The investigation focuses on whether the transaction terms adequately protect Supernus shareholders, creating potential deal-execution and litigation risk.

Analysis

The legal review itself is not a fundamental catalyst: these plaintiff-firm announcements are routinely issued after public M&A announcements and rarely alter consideration absent a credible competing bid, board-process defect, or revised proxy disclosure. The relevant market signal is the SUPN/INDV exchange spread versus the fixed 1.5401-share entitlement; with no cash floor, SUPN holders retain full exposure to INDV share-price volatility through closing, making this a materially different setup from conventional cash merger arbitrage.

For INDV, the key underwriting issue is whether expected CNS-commercial synergies and portfolio diversification outweigh incremental integration costs and any dilution from issuing stock at a potentially depressed valuation. A falling INDV price mechanically lowers the implied value received by SUPN shareholders and may increase shareholder resistance even if the headline exchange ratio remains unchanged. The near-term catalyst path is transaction documentation, shareholder-vote timing, and any antitrust or financing-related conditions; the 6-18 month question is whether combined-company guidance demonstrates accretion rather than merely strategic breadth.

Consensus may overreact to litigation headlines while underpricing the fixed-ratio structure. If the closing probability remains high, the cleaner expression is typically long SUPN/short the appropriate INDV hedge ratio, not outright long SUPN. This thesis is falsified by a material deterioration in INDV operating guidance, a revised transaction timeline, a superior proposal for SUPN, or proxy disclosures indicating a meaningful process challenge.

Key Decisions for Investors

• Do not trade the law-firm announcement directionally; treat it as low-information unless it is followed by a formal complaint, injunction request, revised merger consideration, or a competing proposal.
• Monitor the implied exchange spread: compare SUPN price with 1.5401x INDV. If the annualized gross spread exceeds 12-15% after allowing for borrow, execution costs, and expected closing date, consider a market-neutral long SUPN / short 1.5401 INDV merger-arb position.
• Size any pair trade modestly until the definitive proxy identifies shareholder-vote requirements, termination provisions, regulatory conditions, and expected close date; INDV borrow availability and borrow cost are required inputs before recommending execution.
• For existing INDV holders, use 1-3 month downside protection around proxy and earnings dates rather than adding outright: adverse combined guidance could pressure INDV while simultaneously reducing the marked value of SUPN consideration.
• Exit or materially reduce the arbitrage position if INDV cuts guidance, the transaction timetable slips beyond initial expectations, or the spread narrows below a 6-8% annualized return threshold.